Reference
[1] Lee N, Kim D. Cancer Metabolism: Fueling More than Just Growth.
Mol Cells. 2016 Dec;39(12):847-854.
[2] Labuschagne CF, Zani F, Vousden KH. Control of metabolism by p53
- Cancer and beyond. Biochim Biophys Acta Rev Cancer. 2018
Aug;1870(1):32-42.
[3] Kawada K, Toda K, Sakai Y. Targeting metabolic reprogramming in
KRAS-driven cancers. Int J Clin Oncol. 2017 Aug;22(4):651-659.
[4] Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A,
Vodicka P, Novotny J, Mohelnikova-Duchonova B, Soucek P. Association
between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1,
GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population.
Oncol Rep. 2010 Nov;24(5):1347-53.
[5] Bezzecchi E, Ronzio M, Dolfini D, Mantovani R. NF-YA
Overexpression in Lung Cancer: LUSC. Genes (Basel). 2019 Nov
17;10(11):937.
[6] Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK.
limma powers differential expression analyses for RNA-sequencing and
microarray studies. Nucleic Acids Res. 2015 Apr 20;43(7):e47.
[7] Friedman J, Hastie T, Tibshirani R. Regularization Paths for
Generalized Linear Models via Coordinate Descent. J Stat Softw.
2010;33(1):1-22.
[8] Phan TK, Bindra GK, Williams SA, Poon IKH, Hulett MD. Combating
Human Pathogens and Cancer by Targeting Phosphoinositides and Their
Metabolism. Trends Pharmacol Sci. 2019 Nov;40(11):866-882.
[9] Lacroix M, Riscal R, Arena G, Linares LK, Le Cam L. Metabolic
functions of the tumor suppressor p53: Implications in normal
physiology, metabolic disorders, and cancer. Mol Metab. 2020
Mar;33:2-22.
[10] Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of
oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020
Feb;20(2):74-88.
[11] Vander Heiden MG, DeBerardinis RJ. Understanding the
Intersections between Metabolism and Cancer Biology. Cell. 2017 Feb
9;168(4):657-669.
[12] Agrawal B. New therapeutic targets for cancer: the interplay
between immune and metabolic checkpoints and gut microbiota. Clin Transl
Med. 2019 Aug 27;8(1):23.
[13] Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose
metabolism to suppress cancer progression: prospective of
anti-glycolytic cancer therapy. Pharmacol Res. 2019 Dec;150:104511.
[14] Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms
of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019
Nov;16(11):690-704.
[15] Shen S, Kong J, Qiu Y, Yang X, Wang W, Yan L. Identification of
core genes and outcomes in hepatocellular carcinoma by bioinformatics
analysis. J Cell Biochem. 2019 Jun;120(6):10069-10081.